quaratusugene ozeplasmid
quaratusugene ozeplasmid: 3 clinical trials tracked.
quaratusugene ozeplasmid evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
What is verified about quaratusugene ozeplasmid, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (3)
A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Primary endpoint: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) - Phase 1
A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Pembrolizumab Versus Docetaxel With or Without Ramucirumab in Patients With Previously Treated Non-Small Cell Lung Cancer
Primary endpoint: Recommended Phase 2 Dose (RP2D) - Phase 1
A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer
Primary endpoint: Recommended Phase 2 Dose (RP2D) - Phase 1